Albert Cha, M.D., Ph.D.
Albert Cha, M.D., Ph.D. is a Managing Partner who invests in private and
public biopharmaceutical and medical device companies. Albert draws on
his scientific, medical, and operating experience when working with his
He was an investor in Ceptaris Therapeutics (acquired by Actelion),
Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan),
Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva
Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also
involved in founding NextWave Pharmaceuticals and Prestwick
Pharmaceuticals. Other investments include YM Biosciences (YMI), Dynavax
Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura
Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). He currently
serves on the board of several private biopharmaceutical and medical
device companies. Albert has also served as co-founder of several
portfolio companies. Prior to joining Vivo, Albert worked at Oracle
Corporation in pharmaceutical consulting and at the Palo Alto VA
Hospital as a biomedical engineer.
Albert received his B.S. and M.S. in Electrical Engineering from
Stanford University. He subsequently completed the Medical Scientist
Training Program at UCLA School of Medicine, where he received his M.D.
and Ph.D. in Neuroscience. During his studies, he was elected to Alpha
Omega Alpha and won the prestigious Outstanding Graduate Student Award.
His research in molecular biophysics has been published in highly
respected journals such as Nature and Neuron.